share_log

KeyBanc Adjusts Price Target on AbCellera Biologics to $5 From $7, Maintains Overweight Rating

KeyBanc Adjusts Price Target on AbCellera Biologics to $5 From $7, Maintains Overweight Rating

KeyBanc將abcellera biologics的目標股價從7美元調整爲5美元,維持增持評級。
MT Newswires ·  07/11 21:37

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論